Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo-mechanical caries removal in primary molars
ACTRN12619000440123Phase 2Not yet recruiting
- Sponsor
- Damascus University
- Start
- May 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Brix 3000 and sodium hypochlorite in carious lesion (3 arms), sponsored by Damascus University. Primary endpoint: Assessment of caries removal. Planned start May 2019; status: not yet recruiting.
02
Drugs
Brix 3000sodium hypochlorite
03
Conditions
carious lesion
Beyond the preview
Go deeper on ACTRN12619000440123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000440123.